ProCE Banner Activity

Practical Considerations for Using PARP Inhibitors in Ovarian Cancer: Key ESMO Congress Updates

Clinical Thought
Two expert gynecologic oncologists discuss how to optimally use PARP inhibitors to treat patients with ovarian cancer.

Released: October 19, 2022

Expiration: October 18, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Karyopharm Therapeutics Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab
Institut Gustave Roussy
Paris, France

Alexandra Leary, MD, PhD: consultant/advisor/speaker: Ability, AstraZeneca, Clovis, GlaxoSmithKline, Merck Sharp and Dohme, Zentalis; researcher: Apmonia; AstraZeneca.

Domenica Lorusso, MD, PhD, Prof

Full Professor of Obstetrics and Gynecology
Humanitas University
Head of Gynecology Oncology Medical Unit
Humanitas Hospital San Pio X
Milan, Italy

Domenica Lorusso, MD, PhD: consultant/advisor/speaker: AstraZeneca, Clovis, Genmab, GlaxoSmithKline, Immunogen, Merck Sharp and Dohme, Novartis, Seagen, Sutro.